Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.24 USD | -5.54% | +13.40% | +12.16% |
05-03 | Stifel Starts Phathom Pharmaceuticals With Buy Rating, $24 Price Target | MT |
03-07 | Transcript : Phathom Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 07, 2024 |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+12.16% | 634M | C- | ||
+21.74% | 46.81B | B- | ||
-0.97% | 41.37B | B | ||
+47.07% | 41.29B | A | ||
-3.52% | 28.87B | C | ||
+11.12% | 26.06B | B- | ||
-19.37% | 19.13B | B | ||
+31.18% | 12.39B | C+ | ||
-0.04% | 12.08B | C+ | ||
+0.39% | 11.96B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- PHAT Stock
- Ratings Phathom Pharmaceuticals, Inc.